Twin Capital Management Inc. Acquires New Stake in Halozyme Therapeutics, Inc. $HALO

Twin Capital Management Inc. purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 11,261 shares of the biopharmaceutical company’s stock, valued at approximately $758,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Root Financial Partners LLC purchased a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $25,000. Larson Financial Group LLC grew its stake in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares in the last quarter. Clearstead Advisors LLC grew its stake in Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 265 shares in the last quarter. Penserra Capital Management LLC purchased a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $52,000. Finally, Wexford Capital LP purchased a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $70,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the completion of the sale, the director directly owned 38,498 shares in the company, valued at approximately $2,443,853.04. The trade was a 4.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $53,122,698.20. This represents a 1.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 120,482 shares of company stock worth $8,200,842. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Trading Down 0.7%

Shares of HALO opened at $68.52 on Friday. The firm has a market cap of $8.13 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 0.28 and a beta of 0.89. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a fifty-two week low of $51.06 and a fifty-two week high of $82.22. The firm has a 50 day moving average price of $65.70 and a 200-day moving average price of $68.75.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s quarterly revenue was up 42.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on HALO shares. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, Morgan Stanley lowered their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.67.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.